What insurance plans does Kathleen Monahan, DO accept?

Aetna, Anthem BCBS Colorado, Apostrophe Health, benefitSMART, Carrum, Cigna, Claritev Multiplan / PHCS , Colorado Access, First Health, Humana Medicare Advantage, *Kaiser (depending on market), Medicare, Medicaid, Optum Health / Optum Care CO, PHPprime, Rocky Mountain Health Plans Medicaid Prime, CHP+, Valley, Monument Tier 2 & CO Doctors Plan, SMS, Select Health Colorado Public Option (Exchange) and Medicare Advantage (MA), TRICARE/HealthNET, United Healthcare

Kathleen Monahan, DO

Medical Oncologist / Hematologist

Accepting new patients

Skip to section

Provider Biography

Dr. Kathleen Monahan joined Rocky Mountain Cancer Centers in 2024 as a medical oncologist and hematologist. She is skilled in treating a wide variety of cancers and blood disorders, but her practice focus is on the treatment of all types of breast cancer including hormone-positive breast cancer, HER2-positive breast cancer, triple-negative breast cancer, metastatic breast cancer, and inflammatory breast cancer. She understands the significant variability between breast cancer subtypes and utilizes her expertise to establish a plan that is best suited for each individual.

Dr. Monahan feels that a multi-disciplinary approach is essential to achieving a care plan that is comprehensive, cutting edge, and addresses the unique needs of each patient. She participates weekly in both general and disease-specific tumor boards alongside radiologists, radiation oncologists, surgical oncologists, and pathologists. This collaboration is the gold standard for cancer care and ensures her patients are benefiting from the combined expertise of the group.

Provider Specialties

Benign and Malignant Hematology
Breast Cancer
- Overview
- Breast Cancer Prevention
- DCIS and LCIS
- Genetic Mutations
- HER-2 Positive Breast Cancer
- Hormone Positive Breast Cancer
- Inflammatory Breast Cancer
- Metastatic Breast Cancer
- Triple-Negative Breast Cancer
High-Risk Breast Cancer Prevention
Gastrointestinal Cancers
- Anal Cancer
- Colorectal Cancer
- Esophegeal Cancer
- Liver Cancer
- Pancreatic Cancer
- Stomach Cancer
Gynecologic Cancers
- Overview
- Cervical Cancer
- Ovarian Cancer
- Uterine Cancer
- Vaginal Cancer
- Vulvar Cancer
Lung Cancer
- Overview
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer

Care Philosophy

I believe in a holistic approach to cancer care understanding there are not only physical, but mental, emotional, and spiritual impacts from every new diagnosis. To accomplish this, I tailor each person’s treatment to their individual needs in all of these areas. In addition, I collaborate with each patient to take into account their perspectives related to their diagnosis. I also value a team-based approach to cancer care working alongside compassionate and invested nurses, medical assistants, social workers, nurse practitioners, physician assistants, and more. Together, we strive to build therapeutic relationships founded in trust and mutual understanding so that we may support each person through all phases of diagnosis and treatment.

Care Team

Erin Harner
View Profile

Lisa Tellier
View Profile

Locations

4715 Arapahoe Ave.
Boulder, CO 80303

303-385-2000

Fax: 303-267-4419

8:00am - 5:00pm | M-F

Request Appointment View Details

Skip to section

Education

Fellowship

Medical Oncology & Hematology, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI

Residency

Internal Medicine, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI

Medical School

Rocky Vista University College of Osteopathic Medicine, Parker, CO

Board Certifications

Medical Oncology
Hematology
Internal Medicine

Memberships

American Society of Clinical Oncology
American Society of Hematology

Presentations

Show Presentations
- Real World Statistics on CDK 4/6 Inhibitor Use in Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer with a Focus on Age. San Antonio Breast Cancer Symposium, San Antonio, TX, December 2022.
  
  A Brief Over of Malignancy: Diagnosis, Treatment, and Associated Complications. WI ADCIS Fall conference, Milwaukee, WI, October 2022.
  
  Prognostic Impact of Muscle Attenuation in Metastatic Non-Small Cell Lung Cancer Patients. Department of Medicine Grand Rounds at Medical College of Wisconsin, May 2020.
  
  Muscle Attenuation Is Not a Predictor of Increased Toxicity or Impaired Chemotherapy Response in Metastatic Non-Small Cell Lung Cancer. Multinational Association of Supportive Care in Cancer, San Francisco, CA, May 2019.

Publications

Show Publications
- Monahan, K., George, B. (2023). Liquid Biopsies for Pancreatic Cancer: Is It Ready for Prime Time? In: Pant, S. (eds) Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-38623-7_7
  
  Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):373-379. doi: 10.1038/s41409-023-02178-y. Epub 2024 Jan 4. PMID: 38177221.
  
  Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske TS. Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. Haematologica. 2023 Oct 19. doi: 10.3324/haematol.2023.283210. Epub ahead of print. PMID: 37855051.
  
  Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S. Propylene Glycol (PG)-Free Melphalan Versus PG-Melphalan As Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biol Blood Marrow Transplant. 2020 Dec; 26(12):2229-2236. doi:10.1016/j.bbmt.2020.08.030. Epub 2020 Sep 11. PMID: 32920204.
  
  Monahan K, Michaelis L. Hematologic Therapies Being Studied for Coronavirus: Capitalizing on Progress. The Hematologist. Published July/August 2020.
  
  Wilson S, Osunkwo I, Monahan K, and Little J. Voxelotor: Changing the Disease by Changing the Conformation. The Hematologist. Published November/December 2019.
  
  Monahan K, and Van Hook CJ. Medical image of the week: Complex Arteriovenous Malformation. http://dx.doi.org/10.13175/swjpcc027-16, Southwest Journal of Pulmonary and Critical Care Medicine, Pub Status: Published May 2016.